Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Samson who wrote (18255)	1/28/1999 5:30:00 PM
From: Curt Whitaker	Read Replies (1) \| Respond to of 23519

Accounts receivable are not liquid assets available for use in a stock repurchase, which btw, is the least of Vivus' problems... Nor are Account Payable due tomorrow...

To: Andreas Samson who wrote (18255)	1/28/1999 5:31:00 PM
From: 777 Captain	Read Replies (1) \| Respond to of 23519

Andreas: agree with your observations. What I'm referring to is an announcement by VVUS that they intend to repurchase their stock on the open market, with subsequent followthrough as conditions warrant. If Leland thinks this company is as strong as he indicates, per his actions in negotiations, then I'd want the BOD to step in and do more than talk. It would require EXCELLENT cash management on their part. I figure that's what their Controller gets paid for. It wouldn't take much IMHO to support this one. There's not a whole lot out there. Regards.

To: Andreas Samson who wrote (18255)	1/28/1999 10:38:00 PM
From: Greg22	Read Replies (1) \| Respond to of 23519

Andreas Samson: I think you are picking out the wrong bits of information. 1.) The big point, and I do not think many people caught this, is the new CFO stated that they have a business model that works and is fundamentally sound. The model is not aggressive, but it is very low risk and conservative. 2.) Safety, safety, safety. Muse is safe, Viagra is not. 3.) Leland must have stated at least 3 times that costs will be brought into line with revenues. There is room for further cost reduction at the plant. 3.) Not one person has noticed that domestic revenues increased. International sales are strong, the problem lies in overcapacity. Nor, has anyone stated that the balance sheet is fundamentally strong. Vivus also has an extra million in their pocket. 4.) Now the marketing partner. It is clear that Leland does have deals that he can sign at anytime. I am going out on a limb here, but the problem is some of the possible partners could just buy the company for $80 million rather than pay the $25 milestone. $80 million is a drop in the bucket for Astra/Zeneca. Obviously, this is not in the shareholders best interests. It is my opinion that the business model described by the CFO is enough to interest new investors. We will find out tomorrow. And I do believe we will see a partner much, much sooner than most people expect.